Ahmed O. Kaseb
The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)Scripps MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Cholangiocarcinoma and Gallbladder Cancer Studies, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma(2020)6,911 cited
- → Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma(2021)1,517 cited
- → NASH limits anti-tumour surveillance in immunotherapy-treated HCC(2021)1,187 cited
- → Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study(2023)612 cited
- → Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline(2020)607 cited
- → Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma(2022)590 cited